Clinical trials

  • LUTETIUM (177LU) EDOTREOTIDE for Neuroendocrine tumor | Bronchopulmonary neuroendocrine tumor | SSTR-positive tumour | Pheochromocytoma | Paraganglioma
  • Autologous T-cells transduced with lentiviral vector expressing a chimeric antigen receptor directed against CD19 for CD19-positive relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) | Diffuse large B-cell lymphoma (DLBCL) | Primary mediastinal B-cell lymphoma (PML)
  • AUTOLOGOUS T CELLS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR AGAINST GD2, EX-VIVO EXPANDED for Relapsed/refractory central nervous system tumors
  • AB521 for Solid Tumors|Clear cell renal cell carcinoma
  • PROBENECID for Focal epilepsy
  • VIS171 for Systemic lupus erythematosus | Immune-mediated focal segmental glomerulosclerosis | Alopecia areata
  • SODIUM (R)-2-(2-AMINO-3-(1H-INDOL-3- YL)PROPANAMIDO)-2-METHYLPROPANOATE-PROPAN-2-OL for Geographic atrophy secondary to non-neovascular age-related macular degeneration (non-foveal)
  • Sulfur hexafluoride for Vesicoureteral reflux
  • ZASOCITINIB (zasocitinib) for Plaque Psoriasis
  • Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded for Autosomal recessive osteopetrosis (TCIRG1 mutation)
  • Leniolisib phosphate for Primary immunodeficiency
  • TIMBETASIN ACETATE for Neurotrophic keratitis